Related Experiment Videos
Radiolabeling of dextran with rhenium-188
1MAP Medical Technologies OY, Tikkakoski, Finland. jin.du@mapmedical.fi
Summary
Researchers developed a method to radiolabel dextran with rhenium-188 (188Re) for nuclear oncology. This 188Re-dextran conjugate shows potential for both therapeutic and diagnostic applications in cancer treatment.
Area of Science:
- Nuclear Medicine
- Radiochemistry
- Oncology
Background:
- Rhenium-188 (188Re) is valuable in nuclear oncology for radiotherapy and tumor monitoring due to its nuclear characteristics.
- Development of novel radiolabeled compounds is crucial for advancing therapeutic and diagnostic capabilities in cancer treatment.
Purpose of the Study:
- To describe a method for radiolabeling dextran with rhenium-188 (188Re).
- To evaluate the potential of 188Re-labeled dextran for therapeutic and diagnostic applications in nuclear oncology.
Main Methods:
- Dextran was oxidized to introduce aldehyde groups, then conjugated with cysteine.
- The conjugate was stabilized, and radiolabeling with 188Re was performed using 188Re-gluconate.
- Synthesis and radiolabeling were conducted under anaerobic conditions.
Main Results:
- The radiolabeling efficiency was 60-70% with a radiochemical purity greater than 95%.
- In vitro stability studies showed 50% transcomplexation to cysteine within 1 hour, but good stability was achieved under physiologic conditions with an antioxidant.
- The 188Re-labeled dextran demonstrated potential as a therapeutic and diagnostic agent.
Conclusions:
- The developed method provides a stable 188Re-labeled dextran conjugate.
- This 188Re-dextran conjugate serves as a versatile platform for nuclear oncology applications, including local treatment or as a component in targeted systemic therapies.